A new study from Karolinska Institutet, published in the scientific journal The BMJ, shows how a simple blood analysis can predict the risk of developing severe liver disease. The method may already start to be applied in primary care to enable the earlier detection of cirrhosis and cancer of the liver.

Findings from the UCLA-led trial showed that men who received the radioligand drug went a median of 17.6 months without disease progression, compared with 7.4 months for those who received SBRT alone.

A single course of low-dose radiation therapy may provide a safe and effective alternative treatment option for people with painful knee osteoarthritis according to a new randomized, placebo-controlled clinical trial. The study showed patients with mild to moderate knee osteoarthritis reported significant reductions in pain and improved physical function in the four months after receiving the low dose of radiation, which was just a small fraction of what’s used to treat cancer. Results will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone. The study is the first randomized study to show that a treatment established for later-stage prostate cancer can delay progression and defer hormone therapy when added to high-precision radiation therapy for patients with early metastatic disease. Results will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery — the first predictive biomarker in this setting. Patients with a prostate tumor subtype known as luminal B had much lower risks of recurrence and metastasis when radiation was complemented by hormone therapy, but patients without this tumor subtype saw no improvement. Results of the phase II BALANCE trial (NRG Oncology GU006) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

University of Cincinnati Cancer Center researchers will present abstracts at the American Society for Radiation Oncology (ASTRO) annual meeting Sept. 27 through Oct. 1 in San Francisco.

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Genetic testing can identify patients with HPV-positive throat cancer who may benefit from lower radiation doses, according to Cleveland Clinic research. The study, published in the Journal of Clinical Investigation, builds on a growing body of evidence that radiation treatment can be personalized using tumor genomics, potentially shifting treatment approaches from the norm, where radiation is prescribed at a uniform dose, to one called Genomic Adjusted Radiation Dose (GARD), where radiation is prescribed to a desired effect.